 | | Vol. 16.15 – 18 April, 2024 |
| |
|
|
| The authors reported that the glycolytic metabolite methylglyoxal transiently bypasses Knudson’s paradigm by inactivating the breast cancer suppressor protein BRCA2 to elicit a cancer-associated, mutational single-base substitution signature in nonmalignant mammary cells or patient-derived organoids.
[Cell] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers investigated a large-scale multi-omics cohort and a real-world clinical sequencing cohort including several clinical trials with detailed treatment outcomes, and performed functional validation in patient-derived organoids, tumor fragments, and in vivo models.
[Cancer Cell] |
|
|
|
| The authors showed that DNA damage accumulates due to replication stress during pregnancy, activating the DNA damage response.
[Nature Communications] |
|
|
|
| Investigators reported that chemotherapeutic eribulin induced ZEB1 switch/sucrose non-fermentable (SWI/SNF)-directed chromatin remodeling to reverse epithelial-to-mesenchymal transition that curtailed the metastatic propensity of TNBC preclinical models.
[Cell Reports Medicine] |
|
|
|
| Scientists reported that the long noncoding RNA MILIP supported TNBC cell survival, proliferation, and tumorigenicity by complexing with transfer RNAs (tRNA) to promote protein production, thus representing a potential therapeutic target in TNBC.
[Cancer Research] |
|
|
|
| Researchers showed in mammary stromal fibroblasts that loss of the receptor tyrosine kinase (RTK) negative feedback regulators encoded by Spry1, Spry2, and Spry4 caused upregulation of signaling in multiple RTK pathways and increased extracellular matrix remodeling.
[Cell Death & Disease] |
|
|
|
| The authors investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel of breast cancer cell lines and patient-derived organoids using biochemical methods and cell viability assays.
[British Journal Of Cancer] |
|
|
|
| Scientists identified enhanced sensitivity of ERα-positive breast cancer cell lines to anaplastic lymphoma kinase (ALK) and maternal embryonic leucine zipper kinase (MELK) inhibitors, inducing ERα degradation and diminishing proliferation in specific breast cancer subtypes.
[Scientific Reports] |
|
|
|
|
| The authors summarize the role of FGFR4 in breast cancer, with a special focus on its contribution to subtype switching during metastatic spread and/or induced by therapy.
[British Journal Of Cancer] |
|
|
|
|
| Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ announced the initiation of a new study to evaluate Atossa’s (Z)-endoxifen in combination with abemaciclib, a cyclin-dependent kinase inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer.
[Atossa Therapeutics, Inc.] |
|
|
|
|
| May 31 – June 4, 2024
Chicago, Illinois, United States & Online |
|
|
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
